Therapeutic potential of intravenous 67-gallium in non-Hodgkin's lymphoma.
67-gallium accumulates rather selectively in malignant lymphoid tissue. The isotope has a substantial cytotoxic effect in human-derived cell-lines. 67-gallium was given intravenously to 3 patients with end-stage, resistant large-cell lymphoma. Evaluation of tumour response was done by physical measurements, and CT-scanning together with gallium scintigraphy. Three weekly doses of 20, 40 and 60 mCi respectively caused persistent pancytopenia in 1 patient. Pancytopenia was not observed in 2 other patients given two 40 mCi doses 4 weeks apart. In all 3 patients, some response was noted, be it shortlived and different from site to site. 67-gallium has some cytostatic effect in large cell lymphoma. It seems feasible to start a phase I study to find a tolerable dose to be given every 4 weeks.
Huijgens
P C
PC
Department of Haematology, Free University Hospital, Amsterdam, The Netherlands.
Jonkhoff
A R
AR
Hoekstra
O S
OS
Ossenkoppele
G J
GJ
Teule
G J
GJ
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005710:Gallium Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000532:radiotherapy; D006801:Humans; D007275:Injections, Intravenous; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008479:Mediastinal Neoplasms / Q000473:pathology / Q000532:radiotherapy; D009367:Neoplasm Staging; D011877:Radionuclide Imaging
D005710:Gallium Radioisotopes